Ztalmy

A series of dice with a bag on them illustrating cost cuts

Pharma

Marinus trims workforce by 45% after pair of clinical stumbles

The company last month opted to end development of its flagship seizure drug while exploring "strategic alternatives" to maximize shareholder value.

Zoey Becker Nov 13, 2024 11:26am

dart board miss failure

Marinus to end further Ztalmy development after another trial miss

Oct 24, 2024 12:30pm

hurdles hurdles ahead

With investor lawsuit and trial flop, troubles mount for Marinus

Jun 17, 2024 4:33pm

epilepsy

Once on the scrapheap, Marinus' seizure drug wins FDA approval

Mar 18, 2022 6:48pm